AstraZeneca PLC ADR (AZNN)

1,234.00
+34.00(+2.83%)
  • Volume:
    1,072
  • Bid/Ask:
    1,227.00/1,269.99
  • Day's Range:
    1,212.51 - 1,240.00
  • Type:Equity
  • Market:Mexico
  • ISIN:US0463531089
  • S/N:046353108

AZNN Overview

Prev. Close
1,200
Day's Range
1,212.51-1,240
Revenue
719.24B
Open
1,236.09
52 wk Range
961-1,336
EPS
-
Volume
1,072
Market Cap
3.81T
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,217
P/E Ratio
-
Beta
-
1-Year Change
18.09%
Shares Outstanding
1,549,146,845
Next Earnings Date
-
What is your sentiment on AstraZeneca PLC ADR?
or
Market is currently closed. Voting is open during market hours.

AstraZeneca PLC ADR Company Profile

Employees
76100

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company’s marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyBuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
  • Valneva
    0
    • why this trash going up?
      1
      • already breakout guy.
        0
        • I would await some further drop based on the below article to come in the near future. The company did not perform well with the vaccine and i opened some short positions if my assumptions are correct.
          0
          • https://moneyweek.com/investments/stocks-and-shares/biotech-stocks/603675/astrazenecas-covid-troubles-could-see-it-pull
            0
            • hold long = big victory ✌
              0
              • Finally it reached $60+.
                0
                • AZN and MRK: Lynparza approved in China for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer. Support is strong for the 2 stocks.
                  0
                  • the Delta virus already in USA, but the CDC covered up the truth. in this next 2 weeks, millions of people will get infected, many states may lockdown again.
                    1
                    • Forget about AZN vaccines, they product it at no profit. The Company continues to engage with governments, international organisations and collaborators around the world to ensure broad and equitable access to this well-tolerated and effective vaccine at no profit during the pandemic period.
                      0
                      • The company has been doing a great job so far this year, will continue making profit from COVID-19 vaccines and many other drugs.
                        0
                        • Good news, AstraZeneca said the EU had lost its legal case, the company will deliver vaccines to EU.
                          0
                          • Wow, look at the hug volume, the long awaited $60 to come next week.
                            0
                            • the beginning of the end . the train pulls down.
                              0
                              • CBC News Canada: As per The National Advisory Committee on Immunization (NACI) in Canada announced, the people who took 1st dose of AstraZenaca, as 2nd dose they will take Pfizer-BioNTech COVID-19 Vaccine, or Moderna. Since early May, all provinces have halted the use of AstraZeneca for first doses.
                                0
                                • MOSCOW, June 17 (Reuters) - Moscow is facing a new coronavirus variant that is more aggressive and infectious, and the situation in the city is rapidly deteriorating, Moscow mayor, Sergei Sobyanin said.A new mutation has arrived, a new strain is active. It's more aggressive, it's harder to recover from, it spreads faster. It's much more likely to penetrate a person's immune system," Sobyanin said, according to the RIA news agency.
                                  0
                                  • EU to decide on Astrazeneca's $39 billion Alexion deal by July 5
                                    1
                                    • Once EU approves the deal, AZN will have 5 more profitable drugs to sell worldwide.
                                      1
                                  • AZN vaccines work very well in India and Japan .
                                    1
                                    • AZN Vaccine halted in Italy due to a teenager’s death.
                                      0
                                      • UK study finds AZN vaccines offer 92% protection against hospitalisation from Delta variant
                                        1
                                        • Look at the Gaps, enjoy the speed.
                                          1
                                          • let's go baby, up up & away
                                            1
                                            • all vaccines are effective, experts point out that their efficacy wanes over time, and a booster dose may be needed every year. The company will make profits from Covid-19 vaccines every year.
                                              2
                                              • There is global shortage of coronavirus vaccines, WHO approved AZN vaccine for Emergency Use.
                                                1
                                                • We need to trust scientists, US government and WHO.
                                                  3
                                              • Three speculative pumps a while ago. Be careful. This position is short
                                                0
                                                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.